Is D‑mannose effective for preventing recurrent uncomplicated urinary tract infections in otherwise healthy adult women?

D-Mannose for UTI Prevention: Limited Evidence Does Not Support Routine Use

D-mannose may be considered as a non-antibiotic option for preventing recurrent UTIs in otherwise healthy adult women, but patients must be informed that the evidence is weak and contradictory, with the highest quality recent trial showing no benefit over placebo. 1, 2

Guideline Recommendations

The 2024 European Association of Urology guidelines provide a weak recommendation to use D-mannose for reducing recurrent UTI episodes, explicitly noting that patients should be informed of the "overall weak and contradictory evidence regarding its effectiveness." 1 This stands in stark contrast to strong recommendations for other interventions like vaginal estrogen in postmenopausal women, immunoactive prophylaxis, and methenamine hippurate. 1

The hierarchical approach to recurrent UTI prevention should prioritize interventions with stronger evidence first: 1

• First-line non-antimicrobial measures (strong evidence):

  • Vaginal estrogen replacement in postmenopausal women 1
  • Immunoactive prophylaxis for all age groups 1
  • Methenamine hippurate in women without urinary tract abnormalities 1

• Second-line options (weak evidence):

  • Increased fluid intake in premenopausal women 1
  • Probiotics with proven vaginal flora efficacy 1
  • Cranberry products (low quality, contradictory evidence) 1
  • D-mannose (weak and contradictory evidence) 1

Most Recent High-Quality Evidence Shows No Benefit

The 2024 JAMA Internal Medicine randomized controlled trial represents the highest quality and most recent evidence available. 2 This large, double-blind, placebo-controlled trial conducted across 99 UK primary care centers enrolled 598 women with recurrent UTIs and found:

• No significant difference in the proportion of women experiencing a clinically suspected UTI: 51.0% in the D-mannose group versus 55.7% in the placebo group (risk difference -5%; 95% CI -13% to 3%; P = 0.26) 2
• No statistically significant differences in any secondary outcomes including symptom duration, antibiotic use, time to next UTI, or hospital admissions 2
• The authors explicitly concluded that "d-mannose should not be recommended for prophylaxis in this patient group" 2

This contradicts an earlier 2014 study that showed benefit, but the 2024 trial is methodologically superior with placebo control and larger sample size in a community setting. 2, 3

Mixed Evidence from Other Recent Studies

A 2025 three-arm randomized trial comparing increased hydration, D-mannose, and antibiotic prophylaxis found intermediate results for D-mannose (mean 0.32 episodes/year) compared to antibiotics (0.2 episodes/year) and hydration alone (1.08 episodes/year), though the study was small (75 participants). 4

A 2025 systematic review and meta-analysis of 4 RCTs (890 participants) found no significant difference in recurrent UTIs (RR 0.44; 95% CI 0.18-1.11; P = 0.082) or adverse events between D-mannose and placebo/no treatment, with high heterogeneity (I² = 90%). 5

The 2022 Cochrane review concluded there is "little to no evidence to support or refute the use of D-mannose" and rated the overall evidence as very low certainty due to serious limitations in study design and sparse data. 6

Clinical Application Algorithm

When a patient with recurrent UTIs asks about D-mannose:

1. First, ensure proper diagnosis: Confirm recurrent UTIs via urine culture (≥3 UTIs/year or 2 UTIs in 6 months). 1, 7

2. Prioritize evidence-based interventions first:

   • If postmenopausal: Vaginal estrogen (strong evidence) 1
   • Consider methenamine hippurate (strong evidence) 1
   • Consider immunoactive prophylaxis (strong evidence) 1

3. If patient specifically requests D-mannose or prefers non-antibiotic options:

   • Inform them that the most recent high-quality trial showed no benefit over placebo 2
   • Explain that evidence is weak and contradictory 1
   • If they still wish to try it: typical dose is 2 g daily 2, 3
   • D-mannose is well-tolerated with minimal side effects (mostly mild gastrointestinal) 2, 3

4. Reserve antibiotic prophylaxis for when non-antimicrobial interventions have failed (continuous or postcoital). 1

Important Caveats

• The 2014 study showing benefit compared D-mannose to nitrofurantoin and no treatment (not placebo), which introduces significant bias. 3
• D-mannose combined with vaginal estrogen in postmenopausal women showed no additional benefit beyond estrogen alone in a 2023 trial. 8
• No studies adequately address D-mannose in men, pregnant women, or immunocompromised patients. 7, 6
• The mechanism (preventing bacterial adhesion to uroepithelial cells) is biologically plausible, but clinical efficacy remains unproven. 6

Bottom line: Given the 2024 JAMA trial showing no benefit and the weak guideline recommendation, D-mannose should not be a first-line recommendation, but may be discussed as a low-risk option for motivated patients who understand its limited evidence base and have exhausted or declined more effective interventions.